Trexquant Investment LP purchased a new stake in shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,652 shares of the company’s stock, valued at approximately $240,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of TCRR. Swiss National Bank boosted its position in TCR2 Therapeutics by 15.9% during the first quarter. Swiss National Bank now owns 52,400 shares of the company’s stock valued at $1,157,000 after buying an additional 7,200 shares during the period. BlackRock Inc. boosted its position in TCR2 Therapeutics by 17.8% during the first quarter. BlackRock Inc. now owns 3,066,636 shares of the company’s stock valued at $67,711,000 after buying an additional 463,097 shares during the period. UBS Group AG boosted its holdings in shares of TCR2 Therapeutics by 3,533.7% during the first quarter. UBS Group AG now owns 54,070 shares of the company’s stock worth $1,194,000 after purchasing an additional 52,582 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of TCR2 Therapeutics during the first quarter worth about $106,000. Finally, JPMorgan Chase & Co. raised its stake in TCR2 Therapeutics by 42.3% in the first quarter. JPMorgan Chase & Co. now owns 654,814 shares of the company’s stock worth $14,457,000 after buying an additional 194,667 shares in the last quarter. Institutional investors and hedge funds own 91.77% of the company’s stock.
Shares of TCRR opened at $8.28 on Thursday. The company has a market capitalization of $316.26 million, a P/E ratio of -3.55 and a beta of 2.10. The firm has a 50 day moving average of $13.14 and a 200 day moving average of $16.71. TCR2 Therapeutics Inc. has a twelve month low of $7.62 and a twelve month high of $35.86.
A number of equities analysts recently issued reports on TCRR shares. BMO Capital Markets decreased their price target on shares of TCR2 Therapeutics from $53.00 to $44.00 and set an “outperform” rating for the company in a research note on Friday, August 6th. Truist Securities decreased their target price on shares of TCR2 Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a research note on Monday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price (down previously from $37.00) on shares of TCR2 Therapeutics in a research note on Monday, September 20th. Roth Capital reaffirmed a “buy” rating on shares of TCR2 Therapeutics in a research note on Thursday, August 5th. Finally, Wedbush downgraded shares of TCR2 Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $45.00 to $11.00 in a research note on Friday, September 17th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.00.
TCR2 Therapeutics Profile
TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.
Read More: What is the strike price in options trading?
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.